Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation

Breaking & Recent News aTyr Pharma Inc ATYR

Healthcare Biotechnology

aTyr Pharma, Inc. is a clinical-stage biotechnology company. The Company is leveraging intelligence to translate tRNA synthetase biology into new therapies for fibrosis and inflammation. Its lead therapeutic candidate is efzofitimod, a biologic immunomodulator in clinical development for the treatment of interstitial lung disease (ILD), a group of immune-mediated disorders that can cause... see more

Add To Watchlist

Recent & Breaking News (NDAQ:ATYR)

aTyr Pharma to Present at BIO CEO & Investor Digital Conference

GlobeNewswire February 9, 2021

aTyr Pharma Presents Findings Further Validating NRP2 as a Potential Regulator of Solid Tumor Progression

GlobeNewswire January 25, 2021

aTyr Pharma to Present Poster Highlighting Research Approach for Identifying Receptor Targets for Extracellular tRNA Synthetases

GlobeNewswire January 22, 2021

aTyr Pharma Announces Partner Kyorin Pharmaceutical, Co., Ltd. Completes Subject Visits for Phase 1 Trial of ATYR1923 in Japan

GlobeNewswire January 14, 2021

aTyr Pharma to Present at H.C. Wainwright Virtual BioConnect Conference

GlobeNewswire January 7, 2021

aTyr Pharma Announces Positive Topline Results from Phase 2 Clinical Trial of ATYR1923 in COVID-19 Patients with Severe Respiratory Complications

GlobeNewswire January 4, 2021

aTyr Pharma Announces Completion of Enrollment in Phase 1b/2a Clinical Trial of ATYR1923 in Patients with Pulmonary Sarcoidosis

GlobeNewswire December 21, 2020

aTyr Pharma Announces Third Quarter 2020 Results and Provides Corporate Update

GlobeNewswire November 12, 2020

aTyr Pharma Announces Publication in the Journal mAbs

GlobeNewswire November 11, 2020

aTyr Pharma Announces Discovery of New Receptor Targets for Two tRNA Synthetases from its Pipeline

GlobeNewswire November 10, 2020

aTyr Pharma to Webcast Conference Call Reporting Third Quarter 2020 Financial Results - Management to host conference call and webcast on November 12th at 5:00 pm EST / 2:00 pm PST

GlobeNewswire November 5, 2020

aTyr Pharma Announces Research Collaboration with Medical University of South Carolina

GlobeNewswire October 29, 2020

aTyr Pharma to Participate in ROTH Capital Partners Webinar on COVID-19 Therapeutics in Development on October 28th

GlobeNewswire October 27, 2020

aTyr Pharma Announces Completion of Enrollment in Phase 2 Clinical Trial of ATYR1923 in COVID-19 Patients with Severe Respiratory Complications

GlobeNewswire October 26, 2020

aTyr Pharma to Participate in October Virtual Investor Events

GlobeNewswire October 7, 2020

aTyr Pharma Announces Partner Kyorin Pharmaceutical, Co., Ltd. Doses First Subjects in Phase 1 Trial of ATYR1923 in Japan

GlobeNewswire September 15, 2020

aTyr Pharma Announces $20 Million Common Stock Purchase Agreement with Aspire Capital Fund, LLC

GlobeNewswire September 14, 2020

aTyr Pharma to Present at September Investor Conferences

GlobeNewswire September 9, 2020

aTyr Pharma to Present at Life Sciences Investor Forum on September 17th

GlobeNewswire September 2, 2020

aTyr Pharma Announces Second Quarter 2020 Results and Provides Corporate Update on ATYR1923 Clinical Trial Programs

GlobeNewswire August 13, 2020